Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Interleukin 15 (IL15) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Interleukin 15 (IL15) Products under Development by Stage of Development | 7 | 1 |
| Interleukin 15 (IL15) Products under Development by Therapy Area | 8 | 1 |
| Interleukin 15 (IL15) Products under Development by Indication | 9 | 1 |
| Interleukin 15 (IL15) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Interleukin 15 (IL15) Products under Development by Companies | 12 | 2 |
| Interleukin 15 (IL15) Products under Development by Universities/Institutes | 14 | 2 |
| Interleukin 15 (IL15) Therapeutics Assessment | 16 | 7 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 2 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Interleukin 15 (IL15) Companies Involved in Therapeutics Development | 23 | 3 |
| Amgen Inc. | 23 | 1 |
| Calypso Biotech SA | 24 | 1 |
| Digna Biotech, S.L. | 25 | 1 |
| Interleukin 15 (IL15) Drug Profiles | 26 | 9 |
| AM-0015 Drug Profile | 26 | 1 |
| AMG-714 Drug Profile | 27 | 2 |
| BNZ-1321 Drug Profile | 29 | 1 |
| BNZ-1322 Drug Profile | 30 | 1 |
| CALY-002 Drug Profile | 31 | 1 |
| DB-039 Drug Profile | 32 | 1 |
| Monoclonal Antibody to Inhibit IL-2 and IL-15 for Oncology, Central Nervous System and Gastrointestinal Disorders Drug Profile | 33 | 1 |
| Recombinant Protein to Activate IL-15 for Prostate Cancer and Metastatic Cancer Drug Profile | 34 | 1 |
| Interleukin 15 (IL15) Dormant Projects | 35 | 1 |
| Interleukin 15 (IL15) Discontinued Products | 36 | 1 |
| Interleukin 15 (IL15) Featured News &Press Releases | 37 | 6 |
| May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease | 37 | 1 |
| Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II | 37 | 1 |
| Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting | 38 | 1 |
| Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Celiac Disease Symposium | 39 | 1 |
| Jun 18, 2015: Admune Announces the First-in-Human Study of Heterodimeric IL-15 with Broad Applications for Cancer Immunotherapy | 39 | 1 |
| Dec 15, 2006: Genmab Announces AMG 714 Development Update | 40 | 1 |
| Mar 23, 2004: Amgen Announces Positive Humax-IL15 Interim Phase II Data | 40 | 1 |
| Jan 23, 2003: Genmab A/S Announces FDA Approval To Initiate Phase II Clinical Study Using HuMax-IL15 | 40 | 1 |
| Sep 04, 2002: Genmab Announces Positive Results From Phase I/II Clinical Trial Of HuMax-IL15 For The Treatment Of Rheumatoid Arthritis | 40 | 1 |
| Jul 01, 2002: Genmab Announces The Human Antibody Therapeutic Drug HuMax-IL15 Effectively Treats Psoriasis | 41 | 1 |
| Oct 03, 2001: Genmab Initiates Phase I/II Clinical Trial With HuMax-IL15 For The Treatment Of Patients With Rheumatoid Arthritis | 42 | 1 |
| Appendix | 43 | 2 |
| Methodology | 43 | 1 |
| Coverage | 43 | 1 |
| Secondary Research | 43 | 1 |
| Primary Research | 43 | 1 |
| Expert Panel Validation | 43 | 1 |
| Contact Us | 43 | 1 |
| Disclaimer | 44 | 1 |